Targacept target raised to $34 from $26 at Oppenheimer

Oppenheimer raised its target on Targacept after the firm reported positive data for TC-5214, an adjunctive treatment for major depressive disorder. The firm thinks the drug's efficacy in multiple areas gives it the potential to become the top treatment for the disorder. Oppenheimer maintains an Outperform rating on the stock.